Although subsequent large phase III trials specifically in lung cancer failed to show benefit from canakinumab [152], it should be noted that patients with known cancers were excluded from recruitment in CANTOS, thus still leaving the question open of whether IL-1β blockade could still prove beneficial in preventing cancer mortality in patients with existing CVD. This evidence concerns the gene IL1B and cancer.